The Newborn Screening Translational Research Network (NBSTRN) is marking its 60th anniversary with a two-day virtual meeting celebrating advocacy and research in newborn screening. The event will showcase the expansion of NBS to over 80 conditions through new screening, diagnostic technologies, and therapies.
The special issue highlights innovation across various stakeholders in newborn screening, including researchers, healthcare professionals, and families. Key findings include the development of novel technologies to screen, diagnose, and treat newborns, as well as long-term follow-up studies and NBS expansion.
The 2022 NBS Research Summit explores efforts to discover novel technologies for screening, diagnosis, and treatment of genetic conditions in newborns. Clinicians will present their work on improving treatments for various diseases, including Glutaric Aciduria Type 1 and Sickle Cell Diseases.
The NBSTRN 2022 Network Meeting showcased recent advancements in Newborn Screening (NBS) research, including Whole Genome Sequencing as Screening, Rare Disease advocacy, and Congenital CMV research. The meeting aimed to facilitate policy and research collaborations to improve NBS and rare disease outcomes.
The Virtual NBSTRN Newborn Screening Summit brought together innovators to expand newborn screening research. The event showcased advancements in technology, advocacy, and clinical care for genetic disease detection, highlighting the importance of collaborations between researchers, healthcare professionals, families, and advocacy groups.
The Newborn Screening Translational Research Network (NBSTRN) has launched a new podcast called Newborn Screening SPOTlight, which shares stories of how newborn screening research saves lives every day. The podcast is co-hosted by Drs. Amy Brower and Kee Chan and features interviews with experts in the field.